Exicure, Inc. to Present at the BTIG Virtual Biotechnology Conference
August 04 2021 - 7:00AM
Business Wire
Exicure, Inc.® (NASDAQ: XCUR), a pioneer in gene regulatory and
immunotherapeutic drugs utilizing spherical nucleic acid (SNA™)
technology, today announced that CEO David Giljohann will present
at the BTIG Virtual Biotechnology Conference on Monday, August 9,
2021 at 2:30pm ET. Exicure will also host 1x1 investor meetings
during the conference.
BTIG hosted events are intended for prospective and existing
BTIG clients only. To listen to the live event, please contact your
BTIG representative with interest.
About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company
developing therapeutics for neurology, immuno-oncology,
inflammatory diseases and other genetic disorders based on its
proprietary Spherical Nucleic Acid, or SNA technology. Exicure
believes that its proprietary SNA architecture has distinct
chemical and biological properties that may provide advantages over
other nucleic acid therapeutics and may have therapeutic potential
to target diseases not typically addressed with other nucleic acid
therapeutics. Exicure is in preclinical development of XCUR-FXN a
lipid-nanoparticle SNA–based therapeutic candidate, for the
intrathecal treatment of Friedreich’s ataxia (FA). Exicure’s
therapeutic candidate cavrotolimod (AST-008) is in a Phase 1b/2
clinical trial in patients with advanced solid tumors. Exicure is
based in Chicago, IL and in Cambridge, MA.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210804005299/en/
Karen Sharma MacDougall 781-235-3060 ksharma@macbiocom.com
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jul 2023 to Jul 2024